Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Optimizing Patient Outcomes with JAK Inhibitors
Brett King, M.D, Ph.D and Alexandra Golant, M.D summarize their thoughts on optimizing treatment outcomes for patients suffering from atopic dermatitis with the JAK inhibitor class.
EP: 1.Expert Perspectives on the Rapid Expansion of Atopic Dermatitis Treatments
EP: 2.Atopic Dermatitis Treatment Biological Targets
EP: 3.Use of JAK Inhibitors in Clinical Practice
EP: 4.Importance of Clinical Trial Data, Disease Control, and QoL in Atopic Dermatitis Management
EP: 5.Final Thoughts for Atopic Dermatitis Treatment
EP: 6.Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 7.Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 8.Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 9.Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 10.Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
EP: 11.Expert Perspective on the Care of Patients with Atopic Dermatitis
EP: 12.Role of Disease Severity in Topical vs Systemic AD Treatment
EP: 13.Efficacy and Safety of JAK inhibitors for AD
Now Viewing
EP: 14.Optimizing Patient Outcomes with JAK Inhibitors
Related Videos
Related Content
